JW Pharmaceutical, a South Korean pharmaceutical company, reported a 24% increase in operating profit in the first quarter.

Specialty drug sales up 11%,

[Photo=JW Chugai Pharmaceutical], ‘JW Chugai Pharmaceutical announced on the 8th that based on the separate financial statements for the first quarter of this year, sales increased by 4.0% compared to the same period last year to 178.2 billion won. ‘,

, ‘Operating profit for the first quarter increased by 24.2% year-on-year to 26.7 billion won. Net profit for the same period reached 19.9 billion won, up 18.3% from the previous year. ‘,

, ‘JW Chugai Pharmaceutical explained that this outstanding performance was driven by the growth of original specialty drugs (ETC) that secured cost competitiveness. It also added that the over-the-counter (OTC) business sector also achieved sales growth. ‘,

, ‘Specialty drug sales for the first quarter reached 143.3 billion won, up 10.9% from the previous year (129.3 billion won). The OTC sector recorded sales of 15.5 billion won, a 6.7% increase from the first quarter of last year (14.5 billion won). ‘,

, ‘An official from JW Chugai Pharmaceutical said, “Performance growth continues in the area of original specialty drugs such as Hemlibra (hemophilia treatment) and Libarojet (hyperlipidemia treatment) that have secured competitiveness,” and added, “Based on stable profit realization amidst increasing R&D tasks for self-innovation new drug development, we will expand investment further.” ‘,

,